MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
04/02/18MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
NASDAQ GS | MYOK (Common Stock)
$49.50 + 0.70
04/20/182:22 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.